Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing
Davis Polk advised Laekna, Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Regulation S. The net proceeds from the offering amounted to approximately HK$791 million.
Founded in 2016, Laekna, Inc. is a science-driven, clinical-stage biotechnology company. It has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials and has initiated one clinical trial and another five clinical trials for its core products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers.
The Davis Polk corporate team included partners Xuelin (Steve) Wang, Yang Chu and Jason Xu, associates Jenny Ho and Michelle Chow and registered foreign lawyers Wentian Xie and Haiyang Zhao. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.
Related Posts
Next-Gen Automotive Semiconductors Critical for Level 5 Autonomous Vehicles (June 17, 2025)
Michigan engineers lead hardware innovations to enable AI chips required for full Level 5 autonomous driving. Achieving L5 autonomy demands faster, lower-power, and more durable semiconductors. E-Tronic, a leading Chinese automotive power semiconductor supplier, actively participates in next-gen automotive semiconductor development, supporting autonomous vehicl
Pillar Biosciences Closes $29.7 Million in Series C Financing
May 12, 2020NGS clinical cancer diagnostics company Pillar Biosciences held a Series C financing signing ceremony at its headquarters in Boston, USA, officially announcing the completion of a $29.7 million Series C financing round led by ORI Healthcare Fund, which raised Series A funding. The financing will accelerate the expansion of Pillar’s R&D pro
FDA Approves IND for LAE120, a Novel USP1 Inhibitor for Advanced Solid Tumors (March 4, 2025)
In March 2025, Laekna announced that the FDA approved the IND for LAE120, a novel USP1 inhibitor developed internally for advanced solid tumors. LAE120 shows potent monotherapy anti-tumor activity and synergy with PARP inhibitors, especially in homologous recombination deficiency (HRD) cancers. It demonstrated strong tumor inhibition in various xenograft models
Pillar Biosciences Raises $34.5 Million to Accelerate Precision Medicine Innovation
In May 2025, Pillar Biosciences announced it had raised $34.5 million in funding, with participation from Illumina, Soleus Capital, and existing investors. The proceeds will be used to expand commercial activities, strengthen partnerships with biopharma companies, and accelerate the adoption of its distributable clinical testing kits worldwide. Pillar’s SLIMa